Stocksigma LogoStocksigma Logo

Natural Capsules Reports Q2FY27 Results and API Strategy Update

Natural Capsules reported consolidated revenue from operations of ₹51.15 Cr in Q2FY27, up 12% YoY and 5% QoQ

Natural Capsules Reports Q2FY27 Results and API Strategy Update

Natural Capsules Ltd · Investor Presentation · 16 Nov 2026, 2:57 am

Natural Capsules Reports Q2FY27 Results and API Strategy Update Natural Capsules reported consolidated revenue from operations of ₹51.15 Cr in Q2FY27, up 12% YoY and 5% QoQ. Consolidated EBITDA rose to ₹3.01 Cr with margins at 5.88%, up 781 bps YoY and 358 bps QoQ, while net loss narrowed to ₹4.22 Cr. Growth was driven by converting idle HPMC lines to gelatin. The company added Mankind Pharma and cleared Zydus Lifesciences' audit. In the API unit, seven COPP filings are underway for completion by Mar'27 alongside 16 planned DMF/CEP filings.

Original exchange filing (PDF)

More announcements from Natural Capsules Ltd

All Natural Capsules Ltd announcements